You are here

Home » Content

HÎPERTANSÎF TÎP 2 DİYABETLİ HASTALARDA LOSARTANIN KAN BASINCI VE MİKROALBÜMİNÜRİ ÜZERİNE ETKİSİ

EFFECTS OF LOSARTAN ON BLOOD PRESSURE AND MICROALBUMINUREA IN HYPERTENSIVE TYPE 2 DIABETIC PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Diabetic nephropathy and hypertension are the leading causes of mortalitiy and morbidity in diabetes mellitus type 2patients. Blockage of renin-angiotensin system with ACE inhibitors, retard the progression of diabetic nephropathy. The aim of this study was to determine the antihypertensive and antimicroalbuminuric effects of losartan in type 2 diabetic and hypertensive patients. 17 diabetics (7 female and JO male, aged 54.8±5.46 ) with hypertension were treated with 50mg/daily of losartan for 12 weeks andfollowed for the changes in systemic arterial blood pressure, microalbuminuriea and blood biochemistry. Microalbuminuriea decreased to 19.3±2.7mg/dayfrom 5I.4±4.3mg/day (p<0.005) after treatment. Systolic pressure decreased to 132.2±11.4mmHgfwm 156±J5.4mmHg(p< 0.05) and diastolic pressure decreased to 70.8±15.2 mmHg from 89.3±12.4 mmHg (p< 0.005). Fasting blood glucose , lipids, urea, creatine, derence of creatine and uric acid were not effected unfavourably. In conclusion, losartan reduces blood pressure andmicroalbuminurea but does not effect the blood biochemistry in hypertensive type II diabetic patients.
Bookmark/Search this post with
Abstract (Original Language): 
Diyabetli hastalarda nefropati ve hipertansiyon önemli mortalite ve morbidite nedenidir. Renin-anjiotensin sisteminin ACE inhibitörleri ile blokajının, diyabetik nefropatinin tedavisinde etkin olduğu bilinmektedir. Anjiotensin H'nin blokajı ile de diyabetik nefropatinin progresy onunun yavaşlatılmasında etkili olunacağı düşünülmektedir. Bu çalışmada, tip 2 diyabetli hipertansif hastalarda, anjiotensin II reseptör blokeri olan losartanın, kan basıncı ve mikroalbüminüri üzerine olan etkilerini araştırdık. On yedi (7 kadın, 10 erkek, yaş ortalaması 54.8+5.46) tip II diyabetli hipertansif hastaya 50 mg/gün losartan oral olarak verildi ve 12 hafta süresince kan basınçları, mikroalbüminüri ve kan biyokimyaları takip edildi. Tedavi öncesi 51.4±4.3 mg/dL olan mikroalbüminüri, 19.3±2.7mg/dL değerine düştü (p<0.005). Sistolikkan basıncı 156±15.4 mmHg'dan, 132.2±11.4 mmHg'ya (p<0.05), diyastolik kan basıncı da 89.3+12.4 mmHg' dan 70.8+15.2 mmHg'ya (p<0.005) düştü. Açlık kan şekeri, kan lipidleri, üre, kreatinin, kreatinin klerensi, ürik asit üzerine olumsuz etki gözlenmedi. Sonuç olarak, losartanın, hipertansif tip 2 diyabetli hastalarda mikroalbüminüriyi azalttığı, kan basıncını düzenlediği ve diğer kan biyokimya parametrelerini olumsuz etkilemediği anlaşılmıştır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_325.pdf
  • 1
53-56
  • Turkish

REFERENCES

References: 

1. Magenson CE. Microalbuminurea predicts clinical proteinurea and early mortality in maturity onset diabetes. N Eng J Med 1984;310:356-60.
2. Mattock MB, Morrish NJ, Viberti JC, et al. Prospective study of microalbuminurea, a predictor of mortality in NIDDM. Diabetes 1992;41:736-41
3. Magensen CE, Schmitz O. Diabetic kidney. Med Clin North Am 1988;7:465-92
4. Viberti GC, Walker JD: Diabetic nephropathy, Aetiology and preventation. Diab Met Rev 1998;4:147-
82
5. Sans T, Kawamura T, Matsumae H, et al. Effects of long term enapril treatment on persistent Microalbuminurea in well controlled hypertensive and normotensive NIDDM patients. Diabetes care 1994;17:420-424.
6. Magensen CE. Microalbuminurea as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673-
89.
7. Magensen CE, Christensen CK. Predicting diabetic glomerulopathy, hemodynamic considerations. Diab
Met Rev 1988;4:89-93.
8. Rasmussen BF, Mathiensen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in IDDM. Lancet 1986; 11:1300¬4.
9. Zeller K, Whittaker L, Sullivan P. Effect of restricting dietary protein on the progression of renal failure in patients with IDDM. N Eng J Med 1991 ;324:78-84.
10. Kanauchi M. Inghihare K, et al. Glomerular lesion in patients with NIDDM and microalbuminurea. Int Med 1993;32:753-7.
11.
Ersö
z Ö, Özdoğan O, Ercan N. Diyabetik nefropatinin Mikroalbüminüri döneminde enapril meleat tedavisinin etkinliği. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi. 1992; 1:76-82.
12. Sonbrier F, Corval P. Clinical implications of the molecular biology of the renin-angiotensin system.
Euro heart J 1990;sup D:3-10.
13. Adder G, Nogt C, Artigheugky A. Diabetic nephropathy. Pathogenesis and treatment. 1993;44:313-
19.
14. Kueneke C, Yaculls R, Metzger R. The role of tissue renin-angiotensin systems in hypertension and effects.
Euro Heart J 1990;supp D:i 1-16.
15. Mathiensen ER, Hammel E, Giese L et al. Efficacy of captopril in postponing nephropathy in normotansive IDDM patients with microalbuminurea. BMJ 1990;303:81-7.
16. Zucchelli P, Zuccola A, Barghi M , et al. Long term comparison between caproptil and nifidipine in progression of renal insufficiency. Kidney Int 1992;42:452-8.
17. Schneider M Lerch M Papuri M. Metabolic neutrality of combined verapamil-trandolapri treatment in contrast to beta-blocker-low dose chlortolidone treatment in hypertensive type 11 diabetes. Journal of Hypertension 1996;14:669-77.
55
18. Hasslacher C, Kampe HP, Bastedt A. ACE inhibitors and diabetic nephropathy. Clinical investigator 1993;11:20-4.
19. Bjorck S, Nyberg G, Mulec H. Beneficial effect ot'caproptil on heavy proteinurea in azometic diabetes. NEngJ Med 1995;313:1617-20.
20. Poblas PL, Mortinez FJ. Effects of losartan and diltiazem on blood pressure, insulin sensitivity, lipid
profile and microalbuminurea in hypertensive type 2
diabetic patients. Clin Drug Invest 1998; 16(9): 61-70.
21. Chan JC, Critchley JA, Tamlison B, et al. Antihypertansive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non insulin dependent diabetes meliitus. AM j Nephrol 1997; 17:72¬80.

Thank you for copying data from http://www.arastirmax.com